The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli‐D randomized controlled trial
In Chinese people with T2D suboptimally controlled with OADs, once-daily iGlarLixi provided better glycaemic control with BW benefit and lower hypoglycaemia event rates versus IDegAsp.
PDF的下载单位、IP信息已删除
(2025-6-4)
null
吃葡萄不吐葡萄皮
369ninja
v0id
Criminology34
GingerF
无极微光
YY
学霸业
极限001
风吹麦浪
cdercder
yyds
Elsevier大王
luyue9406
殷勤的紫槐
arniu2008
OK
Maestro_S
yang
皖公网安备34019202002308
